SEC Settles With Drugmaker Akorn Over Revenue Reports
Generic-drug maker Akorn Inc. and two of its former executives formally settled with the U.S. Securities and Exchange Commission Monday over false financial statements Akorn made in 2014 that overstated the...To view the full article, register now.
Already a subscriber? Click here to view full article